Compare AstraZeneca plc (AZN) vs Conagra Brands Inc (CAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Conagra Brands Inc — how do they compare? AstraZeneca plc trades at $158.36 (market cap $248.14B), while Conagra Brands Inc trades at $14.87 (market cap $7.14B). The key difference: AstraZeneca plc is far larger — about 34.8× Conagra Brands Inc's market cap, and Conagra Brands Inc pays the higher dividend (8.2%). Which is the better fit depends on your goals.
| AZN | CAG | |
|---|---|---|
Market Cap | $248.14B | $7.14B |
Sector | Health | Consumer Staples |
52-Week High | $209.48 | $20.02 |
52-Week Low | $147.06 | $12.58 |
Enterprise Value | $275.41B | $14.20B |
Dividend Yield | 2.01% | 8.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
Conagra Brands (CAG) trades at $14.78, down 2.18% today, with a bearish technical signal and neutral oscillators. The company reported a net income margin of -16.99% for 2026, with revenue declining to $11.3B, while 2025 showed stronger profitability. Recent corporate actions include a dividend cut to $0.18 and leadership changes under CEO John Brase, aiming to streamline operations and reduce debt.
The outlook is mixed: low valuation metrics (P/E 10.06, P/S 0.63) offer downside support, but weak growth and margin pressures pose risks. Analyst consensus is cautious with a $13.67 price target, and institutional sentiment is divided amid ongoing turnaround efforts. Key risks include consumer pushback on pricing and execution challenges under new management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →
